Topics

vascular system issues

Problems related to the vascular system, which is made up of vessels carrying blood and lymph fluid through the body.  Also known as the circulatory system.

A review of neurological side effects of COVID-19 vaccination
A Systematic Review of Autopsy Findings in Deaths after COVID-19 Vaccination
Abnormal Clots and All-Cause Mortality During the Pandemic Experiment: Five Doses of COVID-19 Vaccine Are Evidently Lethal to Nearly All Medicare Participants
Acute extensive pulmonary embolism after mRNA SARS-CoV-2 immunization
Adverse events following COVID‐19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopenia
Adverse events of special interest following the use of BNT162b2 in adolescents: a population-based retrospective cohort study
An Update on COVID-19 Vaccine Induced Thrombotic Thrombocytopenia Syndrome and Some Management Recommendations
Analysis of Thromboembolic and Thrombocytopenic Events After the AZD1222, BNT162b2, and MRNA-1273 COVID-19 Vaccines in 3 Nordic Countries
Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study
Comparison of adverse drug reactions among four COVID-19 vaccines in Europe using the EudraVigilance database: Thrombosis at unusual sites
Concerns regarding Transfusions of Blood Products Derived from Genetic Vaccine Recipients and Proposals for Specific Measures
COVID-19 and the Unraveling of Experimental Medicine - Part II
COVID-19 Vaccine-Associated Thrombosis With Thrombocytopenia Syndrome (TTS): A Systematic Review and Post Hoc Analysis
COVID-19 vaccine-induced immune thrombotic thrombocytopenia: An emerging cause of splanchnic vein thrombosis
COVID-19 Vaccine-Related Thrombosis: A Systematic Review and Exploratory Analysis
COVID-19 vaccines – An Australian Review
COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals
COVID-19 Vaccines: A Risk Factor for Cerebral Thrombotic Syndromes
Deciphering deaths associated with severe serious adverse events following SARS-CoV-2 vaccination: A retrospective cohort study
Development of Venous Thromboembolism After COVID-19 mRNA-1273 Vaccine Inoculation
Doctors and Scientists Write to the European Medicines Agency, Warning of COVID-19 Vaccine Dangers for a Third Time
Embalmer with 50+ years of experience verifies Hirschman's story
Explosive: Embalmer reveals 93% of cases have deadly clots caused by the COVID vax
Fibrin drives thromboinflammation and neuropathology in COVID-19
Funeral Director Tells All
Global Advisory Committee on Vaccine Safety (GACVS) review of latest evidence of rare adverse blood coagulation events with AstraZeneca COVID-19 Vaccine (Vaxzevria and Covishield)
Global Safety Assessment of Adverse Events of Special Interest Following 2 Years of Use and 772 Million Administered Doses of mRNA-1273
Inadvertent Exposure to Pharmacologically Designed Lipid Nanoparticles Via Bodily Fluids: Biologic Plausibility and Potential Consequences
Interview with Dr. Charles Hoffe
Letter to the Editor: Long-Term Prognosis of Patients With Myocarditis Attributed to COVID-19 mRNA Vaccination, SARS-CoV-2 Infection, or Conventional Etiologies
My Life in the Thrill Kill Medical Cult
Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection
Portal Vein Thrombosis Might Develop by COVID-19 Infection or Vaccination: A Systematic Review of Case-Report Studies
Potential adverse events in Japanese women who received tozinameran (BNT162b2, Pfizer-BioNTech)
Pulmonary embolism after SARS-CoV-2 vaccination
Research Letter: Age- and Sex-Specific Incidence of Cerebral Venous Sinus Thrombosis Associated With Ad26.COV2.S COVID-19 Vaccination
Reversible cerebral vasoconstriction syndrome and posterior reversible encephalopathy syndrome following vaccination: analysis of the VAERS database and systematic review
Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study
Safety of mRNA Vaccines Administered During the First Twenty-Four Months of the International COVID-19 Vaccination Program
SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19
SARS-CoV-2 Spike Protein Induces Degradation of Junctional Proteins That Maintain Endothelial Barrier Integrity
SARS-CoV-2 Spike Protein Induces Hemagglutination: Implications for COVID-19 Morbidities and Therapeutics and for Vaccine Adverse Effects
SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: implications for microclot formation in COVID-19
Spike Proteins of SARS-CoV-2 Induce Pathological Changes in Molecular Delivery and Metabolic Function in the Brain Endothelial Cells
Stage III Hypertension in Patients After mRNA-Based SARS-CoV-2 Vaccination
Strategies for the Management of Spike Protein-Related Pathology
Thrombocytopenia and Intracranial Venous Sinus Thrombosis after “COVID-19 Vaccine AstraZeneca” Exposure
Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
Thrombosis Development After mRNA COVID-19 Vaccine Administration: A Case Series
Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
1009